联系客服

600535 沪市 天士力


首页 公告 天士力:天士力2024年第三季度报告

天士力:天士力2024年第三季度报告

公告日期:2024-10-26


      证券代码:600535                                                证券简称:天士力

          天士力医药集团股份有限公司

              2024 年第三季度报告

          本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者

      重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。

      重要内容提示:

      公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存

      在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。

      公司负责人闫凯境、主管会计工作负责人蔡金勇及会计机构负责人(会计主管人员)魏洁保证季

      度报告中财务信息的真实、准确、完整。

      第三季度财务报表是否经审计

      □是 √否

      一、 主要财务数据

      (一) 主要会计数据和财务指标

                                                                    单位:元 币种:人民币

                                                                                                                                  年初至
                                                                    本报告

                                                                                                                                  报告期
                                                                    期比上

                                                                                                                                  末比上
                                                                    年同期

                                            上年同期                                                      上年同期              年同期
    项目          本报告期                                          增减变  年初至报告期末

                                                                                                                                  增减变
                                                                    动幅度

                                                                                                                                  动幅度
                                                                    (%)

                                                                                                                                    (%)
                                    调整前          调整后      调整后                        调整前          调整后      调整后

营业收入      2,090,820,349.95  2,179,391,331.09  2,179,391,331.09    -4.06  6,462,559,794.57  6,571,392,090.82  6,571,392,090.82    -1.66

归属于上市

公司股东的    179,892,795.98    325,325,770.76    325,124,986.36    -44.67    842,201,236.32  1,032,429,704.60  1,032,219,095.72  -18.41
净利润
归属于上市

公司股东的    247,705,017.54    362,793,174.37    362,793,174.37    -31.72    982,296,735.66  1,053,796,140.29  1,053,796,140.29    -6.78
扣除非经常

性损益的净
利润
经营活动产

生的现金流        不适用          不适用          不适用      不适用  1,189,929,757.94  1,089,547,053.26  1,089,487,406.49    9.22
量净额
基本每股收

益(元/股)            0.12            0.22            0.22    -45.45            0.56            0.69            0.69  -18.84

稀释每股收

益(元/股)            0.12            0.22            0.22    -45.45            0.56            0.69            0.69  -18.84

加权平均净

资产收益率              1.43            2.65            2.65    -1.22            6.70            8.29            8.28    -1.58
(%)

                                                                                                          本报告期末比上年度末增
                                                                      上年度末

                        本报告期末                                                                            减变动幅度(%)

                                                      调整前                      调整后                        调整后

总资产                      16,834,745,203.85        16,714,285,093.86                    16,714,285,093.86                    0.72

归属于上市

公司股东的                  12,706,974,226.17        12,368,420,072.26                    12,368,420,072.26                    2.74
所有者权益

      注 1:“本报告期”指本季度初至本季度末 3 个月期间,下同。

      注 2:营业收入本年累计金额较上年同期下降 1.66%,其中医药工业收入增长 2.18%,医药商业收

      入下降 25.36%。

      注 3:归母净利润本年累计金额较上年同期下降 18.41%,主要系公司持有的金融资产公允价值变

      动损失高于上年同期及部分产品降价毛利下降所致。

      注 4:扣非归母净利润本年累计金额较上年同期下降 6.78%,主要系公司部分产品降价毛利下降所

      致。

      追溯调整或重述的原因说明:

      公司于 2023 年 10 月同一控制下企业合并 Tasly Healthcare Deutschland GmbH,故本报告期及年初

      至报告期末相应调整了合并报表的比较数据。

      (二) 非经常性损益项目和金额

      √适用 □不适用

                                                                      单位:元 币种:人民币

              非经常性损益项目            本期金额    年初至报告期末        说明

                                                              金额

      非流动性资产处置损益,包括已计提      -127,399.11    -2,549,729.09

      资产减值准备的冲销部分

      计入当期损益的政府补助,但与公司

      正常经营业务密切相关、符合国家政    2,926,034.69    15,818,881.49

      策规定、按照确定的标准享有、对公

司损益产生持续影响的政府补助除外

除同公司正常经营业务相关的有效套                                  主要系公司持有的
期保值业务外,非金融企业持有金融                                  金 融 资 产 Genova
资产和金融负债产生的公允价值变动  -68,264,178.67  -149,249,547.52  Inc.Limited 和永泰生
损益以及处置金融资产和金融负债产                                  物制药有限公司可
生的损益                                                          转债公允价值下降。

除上述各项之外的其他营业外收入和      -721,184.96    -2,732,218.78

支出

减:所得税影响额                    1,509,860.64      933,403.99

  少数股东权益影响额(税后)        115,632.87      449,481.4